Vaccinex Inc

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer's disease.

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer.

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares.

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Vaccinex Inc (NASDAQ: VCNX) tanked an alarming 40% on Wednesday despite it reporting positive early-stage results for its Alzheimer's treatment.  The biotechnology company said its SIGNAL-AD trial established its pepinemab antibody as well-tolerated by patients of AD.

Vaccinex stock tanks 40% despite positive Alzheimer's study update

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease in early June 2024. $8.2 million of new financing in Q1.

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant. The warrants will have an exercise price of $7.64 per share, will be immediately exercisable upon issuance and will expire 5 years from the initial exercise date. The registered direct offering and concurrent private placement are referred to herein as the “Transactions.”

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted basis.

Vaccinex, Inc. Announces Reverse Stock Split

ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company's Board of Directors and the Company's Chief Executive Officer. The securities purchase agreement for the financing provides for the sale of an aggregate of 3,838,544 shares of the Company's common stock (and 1,265,078 common stock equivalents in lieu of common stock) together with common warrants to purchase up to an equal number (5,103,622) of shares of common stock. The shares and warrants are being sold at a combined purchase price per share and warrant of $0.725. The common warrants will have an exercise price of $1.00 per share. The common warrants will be immediately exercisable and will expire five years from the initial exercise date, provided, however, that the Company may call the warrants within 120 days after reporting specified positive topline data in the Company's ongoing SIGNAL-AD phase 1/2a clinical trial of its lead drug candidate, pepinemab, in Alzheimer's disease.

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer's Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer, previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in compliance with Nasdaq's minimum bid price requirement and that Nasdaq could move to suspend trading of the common stock and to delist the Company's securities unless the company appealed Nasdaq's determination.

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y.

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanoma Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanoma

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

ABVC BioPharma

PaxMedica Inc

If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market.

Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch

Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Vaccinex (NASDAQ: VCNX ) stock is climbing higher on Friday after the clinical-stage biotechnology company announced insider buying. These insider trading actions were revealed by Vaccinex in a series of filings with the Securities and Exchange Commission (SEC).

Why Is Vaccinex (VCNX) Stock Up 26% Today?

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced it has entered into securities purchase agreements with healthcare focused institutional investors along-side significant participation from an entity affiliated with the Chairman of the Company's Board of Directors, and existing investors of the Company for the purchase and sale of 9,600,000 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 9,600,000 shares of common stock at a purchase price per share (and accompanying warrant) of $1.00 in its "reasonable best efforts" public offering. The warrants will have an exercise price of $1.00 per share, will be immediately exercisable and will expire five years from the initial exercise date.

Vaccinex Announces Pricing of $9.6 Million Public Offering

Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells

Vaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present data on a new ActivMAb® application on September 28 th and an update on the Phase 1b/2 pepinemab study in patients with PDAC on September 29 th.

Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application

"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer's Disease Conference to be held in Boston on October 24-27, 2023.

Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.

News for Vaccinex Inc Stock (VCNX)